Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations

Rhea-AI Summary

Axion BioSystems has strongly rejected allegations from Agilent Technologies (NYSE: A) regarding patent infringement and false advertising related to its live-cell analysis products. Axion asserts that it does not infringe Agilent's patents and believes these claims are without merit. The company stands by its innovative technology and is prepared to defend its rights in court, anticipating a successful outcome. Axion emphasizes its commitment to advancing live-cell analysis tools to accelerate biomedical research and maintain its position as a market innovator.

Positive

• Axion BioSystems is confident in its technology and believes it does not infringe Agilent's patents.
• The company has a strong commitment to defend its intellectual property rights.
• Axion aims to continue advancing live-cell analysis, positioning itself as a market innovator.

Negative

• The patent infringement allegations may distract from Axion's core business operations.
• Legal proceedings could lead to increased costs and resource allocation towards litigation.

ATLANTA--(BUSINESS WIRE)-- Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising.

As a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its competitors. But when competitors make allegations that are without merit, Axion must robustly defend itself.

At issue are Agilent Technologies, Inc.’s spurious allegations of false advertising and claims that certain of Axion’s live-cell analysis products infringe three Agilent patents. In rebuttal, Axion rejects any claims of patent infringement and stands by the technological capabilities of its products.

Axion is confident that it does not infringe Agilent’s patents and that those patents will ultimately be proven invalid. Axion looks forward to vindicating its rights in court and obtaining a successful outcome against Agilent. Axion BioSystems will continue to advance the frontiers of live-cell analysis as a market innovator to accelerate biomedical discoveries.

About Axion BioSystems

Axion BioSystems, Inc. is a leading life science company focused on next-generation live-cell analysis tools for biomedical research and drug discovery. With innovative systems that monitor complex cellular activity in real time without disturbing the underlying biology, Axion’s technology accelerates scientific discovery with streamlined workflows providing more complete datasets. Headquartered in Atlanta, Georgia, USA, the company has more than 180 employees worldwide. www.axionbiosystems.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005263/en/

Mike Clements

Vice President Marketing, Axion BioSystems

media@axionbio.com

Source: Axion BioSystems, Inc.

FAQ

What allegations has Agilent Technologies made against Axion BioSystems?

Agilent Technologies has accused Axion BioSystems of patent infringement and false advertising related to its live-cell analysis products.

How is Axion BioSystems responding to the patent infringement claims?

Axion BioSystems is vigorously defending itself, asserting that the claims are without merit and that it does not infringe Agilent's patents.

What is Axion BioSystems' confidence regarding the patents in question?

Axion is confident that Agilent's patents will be proven invalid and that it will successfully vindicate its rights in court.

What is the focus of Axion BioSystems as a company?

Axion BioSystems focuses on next-generation live-cell analysis tools for biomedical research and drug discovery.